Detalhe da pesquisa
1.
PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
Int J Gynecol Cancer
; 30(12): 2002-2007, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33046573
2.
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
Lancet Oncol
; 20(9): 1273-1285, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31345626
3.
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
Lancet Oncol
; 19(3): 295-309, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29449189
4.
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.
Lancet Oncol
; 17(8): 1114-1126, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27397040
5.
Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.
J Clin Oncol
; 41(27): 4369-4380, 2023 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37487144
6.
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial.
Int J Radiat Oncol Biol Phys
; 109(4): 975-986, 2021 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33129910
7.
Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial.
Int J Radiat Oncol Biol Phys
; 93(4): 797-809, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26530748